Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$135.99 USD
-1.77 (-1.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $135.92 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$135.99 USD
-1.77 (-1.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $135.92 -0.07 (-0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Lyra Therapeutics, Inc. (LYRA) and Neurocrine Biosciences (NBIX) have performed compared to their sector so far this year.
What's in Store for United Therapeutics' (UTHR) Q2 Earnings?
by Zacks Equity Research
United Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso, Remodulin and Orenitram in the second quarter, as these constitute a vast majority of the total revenues.
What to Expect From Molina Healthcare's (MOH) Q2 Earnings?
by Zacks Equity Research
Molina Healthcare's (MOH) second-quarter results are likely to reflect benefits from higher premiums stemming from Medicaid and Medicare businesses, partly offset by elevated medical care costs.
Here's How Universal Health (UHS) Looks Ahead of Q2 Earnings
by Zacks Equity Research
Universal Health's (UHS) second-quarter results are likely to benefit from sound contributions from Acute Care Hospital Services segment. Increased labor costs might partly hurt results.
Factors Likely to Shape Tenet Healthcare's (THC) Q2 Earnings
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter results are likely to reflect the impact of lower contribution of the Hospital segment to overall revenues. The results might partly benefit from a downtrend in operating expenses.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Neurocrine Biosciences (NBIX) Lags Q1 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -57.58% and 1.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
NVIDIA and Neurocrine Biosciences highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
NVIDIA and Neurocrine Biosciences highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Neurocrine Biosciences (NBIX)
by Kevin Cook
Strong growth for Ingrezza meets company investment in the pipeline, sparking lowered EPS estimates
Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion (ESPR) Beats on Q3 Earnings, Lowers Expense Guidance
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports solid third-quarter results, beating estimates for earnings and sales. However, the stock declines in pre-market trading.
Neurocrine Biosciences (NBIX) Lags Q3 Earnings Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -54.90% and 0.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Q2 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -17.31% and 5.26%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -29.79% and -4.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Neurocrine Biosciences (NBIX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?
by Zacks Equity Research
Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.